

Rapid Molecular Assays for the Diagnosis of Drug-Resistant Tuberculosis [Corrigendum]

Nandlal L, Perumal R, Naidoo K. Infect Drug Resist. 2022;15:4971-4984.

The authors have advised that there is an error in Table 2 on pages 4975 and 4976. The text "\$1240" in the Cost Per Test column for the TRUENAT MTB-RIF Dx (Molbio) 2020 row should read "\$12.40".

This error was introduced by the Editorial staff during the publication process. The correct Table 2 is shown below.

Dovepro

Table 2 Performance of WHO-Endorsed Molecular Diagnostics for Drug-Resistant TB Diagnosis and Drug-Susceptibility Testing

Assay (Manufacturer) Year	Mtb and Drug Resistance (Sensitivity, Specificity) %	DR-TB Category	Cost Per Test	Time to Result	Specimen Types	Benefits	Limitations					
GeneXpert assays												
XPERT MTB/RIF (Cepheid) 2010	Mtb: (85, 98) Drug resistance: RIF (96, 98)	RR-TB	\$10	2 hours	Raw sputum Concentrated sputum sediments	Results available in <2 hours Requires fewer biosafety measures than culture/LPA, so can be used in lower level	Reliant on electricityExpensiveCannot be used to track treatment progress					
XPERT MTB/RIF Ultra (Cepheid) 2017	Mtb (90, 96) Drug resistance: RIF (94, 98)	RR-TB	\$10	2 hours	Raw sputum Concentrated sputum sediments		Requires annual calibration					
XPERT MTB/XDR (Cepheid) 2021	Mtb: none Drug resistance: INH (94.2, 98); FQ (93.1, 98.3); AMK (86.1, 98.9); ETH (98, 99.7); KAN (98.1, 97); CAP (70, 99.7)	RR-TB; MDR-TB; Pre-XDR- TB;	N/A	1.5 hours	Raw sputum Concentrated sputum sediments							
Truenat assay												
TRUENAT MTB- RIF Dx (Molbio) 2020	Mtb: none Drug resistance: RIF (84, 97)	RR-TB	\$12.40	I hour	Sputum Extrapulmonary body fluids	 Results available in <1 hour Multi-platform: can be used for hepatitis C, Human Papillomavirus, SARS-CoV2 	Several manual steps that need to be performed by skilled personnel					

Moderate complexity automated NAATs										
RealTime MTB RIF (Abbott) 2019	Mtb: none Drug resistance: RIF (94.8, 100); INH (88.3, 94.3)	RR-TB; MDR-TB	N/A	10.5 Hours	Raw sputum Bronchial alveolar lavage NALC sediment of sputum or bronchial alveolar lavage	High sample throughput Each assay has specific multi-platform benefits for HIV-I, HBV, HCV, HPV, SARS-CoV2	Reliant on electricity Expensive equipment and specialised training required			
BD MAX MDR- TB (Becton Dickson) 2021	Mtb: none Drug resistance: RIF (90, 95); INH (82, 100)	RR-TB; MDR-TB	N/A	4 hours	Raw sputum Concentrated sputum sediments					
Cobas MTB-RIF/ INH (Roche) 2021	Mtb: none RIF (97.2, 98.6); INH (96.9, 99.4)	RR-TB; MDR-TB	N/A	4.5 hours	Raw sputum Sputum sediment Bronchoalveolar lavage					
FluoroType MTBDR (Hain) 2021	Mtb: none Drug resistance: RIF (98.9, 100); INH (91.7, 100)	RR-TB; MDR-TB	N/A	3 hours	Decontaminated sputum					
Line probe assay	s									
GenoType MTBDR <i>plus</i> (Hain) 2008	Mtb: none Drug resistance: RIF (98.2, 97.8); INH (95.4, 98.8)	RR-TB; MDR-TB	\$7.50	5 hours	Decontaminated sputum Cultured material (solid/ liquid medium)	 Can be performed from pulmonary specimen and from culture material Results are obtained in 5hrs Fast detection of INH and RIF resistanceallows early, appropriate treatment, which reduces transmission and spread of MDR-TB. 	 Cannot fully replace methods like conventional cultures Not as fast as Xpert Requires complex laboratory infrastructure and expensive equipment Requires well-trained staff Requires BSL3 High number of uninterpretable results is high Target coverage is limited to the main mutations 			
GenoType MTBDRs/ (Hain) 2016	Mtb: none Drug resistance: FLQ (100, 98.9); AMK (93.8, 98.5); CAP (86.2, 95.9)	RR-TB; MDR-TB	\$7.50	5 hours	Decontaminated sputum Cultured material (solid/ liquid medium)					

Abbreviations: HIV, human immunodeficiency virus; Mtb, Mycobacterium tuberculosis; TB, tuberculosis; RR-TB, rifampicin-resistant tuberculosis; MDR-TB, multidrug-resistant tuberculosis; N/A, not applicable; RIF, rifampicin; INH, isoniazid; FLQ, fluoroquinolone; AMK, amikacin; KAN, kanamycin; ETH, ethionamide; CAP, capreomycin.

Nandlal et al Dovepress

Infection and Drug Resistance

Dovepress

Publish your work in this journal

Infection and Drug Resistance is an international, peer-reviewed open-access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventive strategies to minimize the development and spread of resistance. The journal is specifically concerned with the epidemiology of antibiotic resistance and the mechanisms of resistance development and diffusion in both hospitals and the community. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

 $\textbf{Submit your manuscript here:} \ \texttt{https://www.dovepress.com/infection-and-drug-resistance-journal} \\$

